Magnesium Glycinate Supplement

## What it is Magnesium glycinate is magnesium bisglycinate, a chelated salt in which one magnesium ion is bound to two glycine molecules through coordination bonds. The chelation chemistry was developed and commercialized by Albion Laboratories (now Balchem) starting in the 1960s, with their patented TRAACS process becoming the de facto standard for high-bioavailability mineral chelates. The patent has since expired, and most third-party magnesium glycinate sold today is structurally equivalent to the original Albion product, though purity and chelation completeness vary by manufacturer. Elemental magnesium is the eleventh most abundant element in the human body, with the average adult holding roughly 25 grams total, around 60% in bone and most of the remainder in soft tissues and intracellular compartments. Only about 1% of total body magnesium sits in serum, which is why a normal serum magnesium reading does not rule out tissue depletion. Roughly half of US adults consume below the RDA (310 to 420 mg/day depending on age and sex), and population-level subclinical insufficiency is common enough that supplementation is defensible even without a measured deficiency. Magnesium glycinate is a dietary supplement in essentially every jurisdiction. WADA does not list it. The form is favored in functional and integrative medicine settings because of its tolerability profile rather than because of any unique therapeutic effect; the magnesium ion is the active species, and what changes between salts is absorption efficiency and GI side effects. ## Mechanism of action Magnesium is a cofactor for over 300 enzymatic reactions, including all reactions involving ATP (which is functionally MgATP at physiological pH), DNA and RNA synthesis, protein synthesis, and neurotransmitter regulation. It also serves as a voltage-dependent antagonist at NMDA glutamate receptors, where it sits in the channel pore at resting membrane potential and gates calcium flux. This NMDA modulation is the most defensible single mechanism for the calming and sleep-supportive effects observed at supplementation doses. The glycine moiety is not pharmacologically inert. Glycine is itself an inhibitory neurotransmitter at glycine receptors in the spinal cord and brainstem and a co-agonist at NMDA receptors at lower concentrations. Several small trials (Inagawa 2006, Bannai 2012) have reported that 3 g of glycine before bed reduces sleep onset latency and improves subjective sleep quality. The doses of glycine delivered by a typical 300 mg elemental magnesium glycinate serving are far below 3 g, but the fact that glycine has independent sleep effects is part of why the chelate is preferred for evening dosing. Fractional absorption of magnesium varies substantially by salt. Magnesium oxide, the cheapest and most common form, has fractional absorption of roughly 4%. Magnesium citrate sits around 25 to 30%. Glycinate, malate, and threonate sit in the 30 to 40% range in human studies. The differences matter at the dose levels typically used: a 400 mg elemental dose of oxide delivers around 16 mg of absorbed magnesium, while the same elemental dose as glycinate delivers closer to 120 to 140 mg. ## Evidence base by outcome ### Sleep onset and quality The Abbasi 2012 trial (n=46 elderly insomniacs, 500 mg/day magnesium oxide for 8 weeks) reported a 17 minute reduction in sleep onset latency and improved ISI scores, with corresponding changes in serum cortisol and renin. The form was oxide rather than glycinate, but the magnesium ion is the active species and the result generalizes. A 2021 systematic review (Mah and Pitre) covering 7 RCTs and 5 observational studies in adults with insomnia or poor sleep concluded that supplementation produced modest improvements in subjective sleep quality (PSQI), with effect sizes around 0.4 to 0.6 standard deviations. Effects are most consistent in older adults and in individuals with low dietary intake at baseline. ### Anxiety and stress A 2017 systematic review (Boyle) covering 18 trials reported small but consistent reductions in subjective anxiety scales at 200 to 600 mg/day for 4 to 12 weeks. The effect size is smaller than first-line pharmacotherapy and smaller than ashwagandha at typical doses, but the safety profile is favorable enough that magnesium is a reasonable layer in a non-pharmacological anxiety stack. A trial by Pickering 2020 (n=264, 300 mg Mg + 30 mg vitamin B6 versus Mg alone) reported larger anxiety reductions in the combination arm, suggesting the B6 pairing has additive value. ### Migraine Magnesium has the strongest evidence base of any nutritional intervention for migraine prophylaxis. Six trials at 400 to 600 mg/day for 8 to 12 weeks have reported roughly 40 to 50% reductions in attack frequency in adults with frequent migraine. The American Headache Society guidelines list magnesium as a Level B recommendation for migraine prevention, alongside riboflavin and CoQ10. The mechanism is plausibly NMDA modulation plus vasoreactivity effects. ### Muscle cramps A Cochrane review found mixed evidence for magnesium in idiopathic muscle cramps in older adults. The signal is real in pregnancy-related cramps and in cramp-prone athletes, smaller and inconsistent in unselected older adults. Reasonable to try for nocturnal cramps; reasonable to discontinue if there's no effect by 4 weeks. ### Insulin sensitivity and metabolic health In magnesium-deficient adults, supplementation produces small but consistent improvements in HOMA-IR and fasting glucose at 300 to 400 mg/day for 4 to 16 weeks. Effects in non-deficient adults are negligible. The cardiovascular signal is similar: meaningful in deficient populations, weak in replete adults. Treat magnesium supplementation as deficiency repletion rather than as a metabolic intervention. ### Bioavailability versus other forms Direct absorption studies (Walker 2003, Schuette 1994) consistently show glycinate, citrate, and malate outperforming oxide by a factor of 5 to 8 at equivalent elemental doses, and outperforming sulfate and chloride by a factor of 2 to 3. The GI tolerability difference is at least as important as the absorption difference: at 400 mg elemental, oxide produces loose stools in roughly 30 to 40% of users, citrate in 15 to 25%, and glycinate in under 10%. This is the practical case for paying the premium. ## Dosage and protocols The RDA is 310 to 420 mg elemental magnesium per day depending on age and sex. Most supplementation protocols add 200 to 400 mg elemental on top of dietary intake, which lands typical total exposure in the 500 to 800 mg range. Magnesium glycinate is sold both as 'mg of magnesium glycinate' (the chelate) and 'mg of elemental magnesium', and the difference is large: a 1,000 mg magnesium glycinate capsule typically delivers around 200 mg elemental. Read the supplement facts panel rather than the marketing copy. Dosing is typically once daily in the evening, 30 to 60 minutes before bed, to leverage both the sleep effects and the convenience of a single bedtime habit. Splitting the dose morning and evening is also reasonable and may improve absorption at higher total doses, since fractional absorption decreases as single-dose size increases. No cycling is required. Continuous daily use is the standard approach. Total body magnesium pools take weeks to repletewhen depleted, and discontinuation produces no withdrawal effects. The upper limit set by the Institute of Medicine for supplemental magnesium is 350 mg elemental per day, set primarily to avoid GI side effects rather than systemic toxicity. Supplementation above this level is common in clinical practice and is generally well tolerated in healthy adults; the bound is conservative. ## Side effects and safety GI side effects (loose stools, mild cramping) are the most common adverse effect at any magnesium dose and are dose-dependent and form-dependent. Glycinate has the lowest incidence at equivalent elemental doses among commonly used forms. If a chosen brand of glycinate produces loose stools at 200 mg elemental, the most likely explanation is that the chelation is incomplete and you are getting partial salt or oxide content; switching brands often resolves it. Contraindications are narrow and almost entirely renal. Severe renal impairment with eGFR below 30 raises hypermagnesemia risk because the kidney is the primary excretion route. Heart block, particularly second- or third-degree AV block, is a relative contraindication because of magnesium's effect on AV nodal conduction. Myasthenia gravis is a contraindication because magnesium can potentiate neuromuscular blockade. Pregnancy and lactation at RDA-equivalent doses is well-tolerated; avoid mega-doses without clinician input. Drug interactions worth noting: magnesium chelates tetracycline and fluoroquinolone antibiotics and bisphosphonates, reducing absorption of the antibiotic by up to 50%. The fix is dose separation by 2 to 4 hours rather than discontinuation. Potassium-sparing diuretics raise hypermagnesemia risk in renal impairment. PPIs reduce magnesium absorption with chronic use, which is one mechanism behind PPI-associated hypomagnesemia. ## Stack interactions and timing Magnesium glycinate combines naturally with melatonin (timing-aligned for sleep) and ashwagandha (mechanism-orthogonal stress and sleep stack). Pairing with vitamin B6 (P5P) shows small additive effects on anxiety and PMS symptoms in trials. Calcium and magnesium absorb through partially shared transporters; large doses taken simultaneously modestly reduce magnesium absorption, but the effect is small enough that the standard practice of taking them at different times is precautionary rather than essential. Evening dosing makes the most sense for the sleep-supportive use case. Morning dosing is fine for general repletion. Taking magnesium glycinate with food blunts both the absorption and the GI side effects modestly; the net effect on absorbed magnesium is small. ## Practical notes Buy a brand that lists the elemental magnesium content prominently and uses a recognized chelate source (Albion/Balchem TRAACS is the long-standing standard, and many brands credit it on the label). Avoid 'magnesium glycinate' products where the label only shows total chelate weight without elemental, since this often correlates with incomplete chelation and inflated apparent dose. Magnesium oxide is significantly cheaper and is fine for laxative use; it is a poor choice for repletion. Magnesium citrate is a reasonable middle option with better bioavailability than oxide and a lower price than glycinate. Magnesium threonate is marketed for cognitive effects with weak supporting evidence and a substantial price premium; the case for paying it is thin. Expect 2 to 4 weeks before noticing repletion effects. Sleep effects often appear faster (within a week) when low magnesium status is the limiting factor. Loose stools at any dose are a signal to either switch forms or reduce the dose. Storage is unremarkable; cool and dry, away from moisture, and the chelate is shelf-stable for the labeled period.